Orchid Q1 Revenues Fall 14 Percent; Company Will Remain on Nasdaq, but Plans Management Changes | GenomeWeb

NEW YORK, June 22 (GenomeWeb News) - Orchid Cellmark said today that its first-quarter revenues dropped 14 percent as net losses ballooned to $6.6 million from $1.7 million in the year-ago period. 

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.